| Description | Bevifimod (PRTX-100), a highly purified variant of Staphylococcal protein A (SpA), is utilized in research on idiopathic thrombocytopenic purpura (ITP) [1] [2]. |
| In vitro | Bevifimod（PRTX-100；浓度分别为250、25及2.5 ng/mL；作用时间48小时）抑制人类外周血单核细胞(PBMC)对W632调理血小板的吞噬反应[1]。 |
| In vivo | Bevifimod（PRTX-100；2.5-250 μg/kg；静脉注射；每两周一次；连续4周）在1-2周内将小鼠血小板计数提升至正常水平，实验期间未观察到小鼠死亡[2]。 |
| Synonyms | PRTX-100 |
| molecular weight | N/A |
| CAS | 2223113-32-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |